FDA hearing on psychedelic approval centers on access and safety

The FDA held a public hearing as it moves toward what could be the first approval of a psychedelic medicine, seeking input on how such drugs should be used, monitored, and studied in the real world.

A major theme was access:
speakers asked who would be allowed to administer the treatment, how patients would reach it, and whether insurance coverage and reimbursement would make it broadly available.

Safety concerns were front and center, including provider misconduct, the need for patient screening, supervision during treatment, and known risks such as cardiac issues.

The hearing also focused on provider training and credentialing, clinic capacity, follow-up care, and collecting long-term safety data so that real-world outcomes are tracked beyond the trial setting.

Some speakers warned that FDA approval would carry significant cultural weight and could increase interest in psychedelic use outside regulated settings, making safeguards especially important.